In vivo studies combining an antagonist for colony-stimulating factor 1 receptor (CSF-1R) with anti-PD1 resulted in better control of tumor growth [201], while in vitro studies showed that this was mainly mediated by hampering activation of suppressive myeloid cells and by reinvigoration of T and NK cells [202]. The gene discussed is CSF1R; the disease is neoplasm.